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ABSTRACT
Drug related-problems pose additional worse outcomes in 
cancer patients treated with chemotherapy. A vital role of the 
clinical pharmacist is the detection and prevention of drug-
related problems. The provision of patient education is an 
important step to reduce and prevent drug-related problems 
during chemotherapy administration. The objective of this 
study was to assess the occurrence of drug-related problems 
and the importance of effective provision of patient education 
and appropriate recommendations by the clinical pharmacist 
in reducing and solving of these problems in diabetic patients 
suffering from cancer.
A prospective study carried out on 50 diabetic patients as 
a single group with new diagnosis of diverse cancer types 
eligible for chemotherapy adminitration recruited between 
September 2014 and April 2015 at the oncology unit in one 
of the Teaching and Research Hospital (Istanbul-Turkey). 
Drug-related problems were evaluated, and proper patient 
education alongside pharmacist recommendation regarding 
chemotherapy was provided during the required chemotherapy 
protocol schedule. (n=65) of the drug-related problems were 
contributed to inappropriate IV fluid selection; (n=33) were 
attributed to low drug dose prescribed, and (n=30) to high 
drug dose prescribed. Drug-related problems totally solved 
due to clinical pharmacist recommendations were 69.57% 
(n=80). There was a significant increase in the occurrence of 
paleness (P=0.0001); urinary frequency (P=0.003); loss of 
appetite (P=0.0001), nausea (P=0.0001), vomiting (P=0.0001); 
and numbness (P=0.0001). A significant decrease in the 
occurrence and severity of chemotherapy-related adverse 
effects was observed as a mild urinary frequency (P=0.0001) 
and mild vomiting (P=0.0001) after the clinical pharmacist 
recommendations and provision of patient education.
Results of this study revealed that diabetic cancer patients are 
definitly prone to the occurrence of drug-related problems 
and adverse drug reactions. Clinical pharmacist is expected to 
provide a well-defined education and care to those patients and 
the outcomes of pharmacist recommendations may diminish 
and prevent many drug-related problems and adverse drug 
reactions and by this, influence patients’ desire to complete the 
course of chemotherapy.
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Influence of Pharmacist Recommendations for Chemotherapy-Related 
Problems in Diabetic Cancer Patients
Introduction
Diabetes mellitus (DM) and cancer are considered to be the 
most common severe conditions with worse effects on general 
health (1). According to the Pharmaceutical Care Network 
Europe (PCNE) classification, drug related-problem is 
defined as ‘an event or circumstance involving drug therapy 
that actually or potentially interferes with desired health 
outcomes’ (2). Drug related-problems (DRPs) include many 
issues such as adverse drug reactions (ADRs), unnecessary 
drug therapy, inappropriate choice of drugs, and untreated 
conditions. Drug related-problems are associated with a 
prolonged hospitalization, increased economic burden, and 
an almost 2-fold increased risk of substantial morbidity and 
mortality. It also affects the patient’s recovery and is a major 
limitation in providing healthcare to the patient (3-5).
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Rational and safe drug use is greatly important since patient´s 
health is majorly influenced by the occurrence of adverse 
drug reactions. Adverse drug reactions are considered one of 
the main problems as they can increase the rate of morbidity 
and mortality. In addition, they can impose a remarkable 
financial burden on healthcare systems (6,7). Adverse drug 
reaction is defined as a response to a drug which is a noxious 
and unintended, and occurs at doses normally used for the 
prophylaxis, diagnosis, or therapy of disease (8). Cancer 
chemotherapies are associated with numerous adverse drug 
complications which often result in dose reductions or 
treatment delays leading to compromising clinical outcomes 
or even mortality (9). Despite these facts, ADRs still do 
not consider as a relevant problem by a large proportion 
of healthcare professionals (10). Patients and healthcare 
professionals should have a profound attention to prevent 
unnecessary drug treatment and subsequent ADRs (11). The 
most important step of the clinical pharmacist is a reduction 
and effective management of ADRs in cancer therapy. This 
is done by the provision of sufficient and essential pre-
chemotherapy education including those about the possible 
occurrence of side effects and the proper ways for self-
care management (12). Many studies indicate that patient 
education can decrease certain treatment-related issues, 
improve physical and psychosocial outcomes, influence 
patients’ desire to complete the course of chemotherapy and 
finally improve patients´quality of life (12-14).
Aim of the study
The objective of this study was to evaluate the occurrence 
of DRPs during chemotherapy administration and the 
importance of effective provision of patient education 
and appropriate reccommendations offered by the clinical 
pharmacist on the occurrence of these problems in diabetic 
patients suffering from cancer.
Methods
Study Design and Patients Selection
This was an observational prospective study recruited 
between September 2014 and April 2015. The study approved 
by the Ethical Committee (Date and No.: 27-06-2014-1-). It 
was conducted at the oncology unit in one of the Teaching and 
Research Hospital in Istanbul after a permission (Date: 17-
07-2014/ No.: 35778018-770-) from the General Secretaries 
of the South Provincial Public Hospitals at Istanbul-Turkey.
A total of 50 out of 59 diabetic patients with new diagnosis of 
diverse types of cancers eligible for different chemotherapeutic 
protocols were recruited after meeting the inclusion criteria 
at the oncology unit. Inclusion criteria included patients over 
the age of 18 years, diabetic patients with new diagnosis of 
cancer eligible for chemotherapy. Patients who expressed 
willingness to take part and to abide by this study’s rules. 
Were provided with additional written information and 
were asked to sign the study consent form. Exclusion criteria 
included patients with neoadjuvant chemotherapy, patients 
who were receiving radiotherapy concomitantly, and patients 
who expressed willingness to withdraw from the study.
Basically, patient data were collected from the medical 
records of the patients. Any further information requied 
for this study were collected by the researcher clinical 
pharmascist via face-to-face interview with the patients for 
reporting details involving patients’ sociodemographic data, 
knowledge about medications being prescribed, and lifestyle 
manners. Diabetic cancer patients received regular patient 
counseling regarding chemotherapy administration. The 
patient counseling included of correct and proper medication 
use, how to overcome any problems regarding chemotherapy 
taking, possible occurrence of adverse reactions and their 
proper management. These advices were reinforced at regular 
appointments of the chemotherapy schedules. The clinical 
outcomes regarding DRPs and ADRs of chemotherapy were 
followed at the 1st reading (after the 2nd cycle of receiving 
the chemotherapeutic regimens), and the 2nd reading (at 
the end) of the required chemotherapy protocol schedule. 
The researcher clinical pharmacist collaborated with other 
healthcare professionals to augment the counseling and 
patients were referred to specialists when there was a need. 
The assessment of DRPs was based on Pharmaceutical Care 
Network Europe V6.2 which deals with nature, prevalence, 
and incidence of DRPs (2). The assessment of ADRs due to 
chemotherapy administration was evaluated through the 
provision of specific adverse effects questionnaire. Those 
adverse effects were categorized as mild, moderate, and 
severe (15).
Statistical Analyses
The SPSS 16.0 Package was used for statistical analysis. 
Continuous variables were expressed as mean ± SD and 
categorical variables were reported as number (frequency). 
Chi-Square Test or Fisher’s Exact Test was performed 
on categorical variables. The results were assumed to be 
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significant when the p< 0.05 threshold was reached by all 
statistical analyses.
Results
The characteristics of the study population are presented in 
(Table 1). The mean age was 60.98±8.99 years old at a range 
of 34-77 years. Most of the patients were females (58%), had a 
previous family history of cancer (66%). Majority of patients 
were non cigarette smokers (82%), married (96%), with a 
waist circumference of (91.02±19.72 cm), and had a primary 
level of education (62%). All patients were suffering from 
type 2 DM (100 %). Breast carcinoma was the most common 
type of cancer (16%) followed by (14%) Non-Samll Cell 
Lung Carcinoma (NSCLC). Most of the participants recieved 
chemotherapy regimens every 21 days (66%).
Table 1. Demographic and Clinical Patients’ Characteristics
Parameter n= 50 
(%)
Gender
Males
Females
21 (42%)
29 (58%)
Mean Age (year)±SD 60.98±8.99 (34-77 yr)
Cancer Family History
Yes
No
33 (66%)
17 (34%)
Marital State
Married 48 (96%)
Single 2 (4%)
Waist Circumference (cm) 91.02±19.72
Cigaratte Smoking
Yes 9 (18%)
No 41 (82%)
Education Level
Yes (Primary) 31 (62%)
Yes (Secondary) 2 (4%)
No 17 (34%)
Type of DM
Type 1 0 (0%)
Type 2 50(100%)
DM Length (year)±SD 6.46±5.18
Cancer Type
Breast CA 8 (16%)
Pancreas CA 5 (10%)
NSCL CA 7 (14%)
Non-Hodgkin’s Lymphoma 1 (2%)
Rectum CA 4 (8%)
Colon CA 3 (6%)
Stomach CA 0 (0%)
Others 22 (44%)
Previous
Chemo-radiotherapy
Yes 17 (34%)
No 33 (66%)
Cancer Therapy Schedule
Every 7 days 11 (22%)
Every 14 days 6 (12%)
Every 21days 33 (66%)
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Table (2) presents the assessment of DRPs during 
chemotherapy administration. At the drug selection level, 
the results of our study showed that (n=65) of the DRPs were 
contributed to inappropriate IV fluid selection, amount of IV 
fluid administration, and IV incombatibility; DRPs (n=33) 
was attributed to low drug dose prescribed, and (n=30) to 
high drug dose prescribed. At the drugs use process level, 
(n=15) of DRPs were related to a wrong drug use. At the 
patient level, (n=15) of DRPs were reported as patients’ 
forgetting to use the medicines.
Table 2. Drug-Related Problems Assessment During Chemotherapy Administration
Domain Cause Number of occurrence
(n= )
Drug selection
The cause of the DRP is related to the selection of the 
drug
Inappropriate drug selection (mainly IV incombatibility, amount 
of IV fluid administration, IV fluid selection) 65
Inappropriate combination of drugs, or drugs and food 1
Drug dose too low 33
Drug dose too high 30
Drug use process
The cause of the DRP can be related to the way 
the patient uses the drug inspite of proper dosage 
instructions (on the label)
Wrong drug taken/administered 15
Patient
The cause of the DRP can be related to the personality 
or behaviour of the patient.
Patient forgets to use/take drug 15
Table (3) shows the effect of clinical pharmacist 
recommendations on the outcomes of DRPs during 
chemotherapy administration. At the prescriber level, (n=91) 
of the recommendations were approved by the prescriber. 
At the patient/ career level, patient counseling provided 
by the researcher clinical pharmacist represented (n=50) 
of the recommendations, (n=31) of the recommendations 
reported as patient referred to prescriber, and (n=12) of the 
recommendations provided as oral education given to family 
member/caregiver of the patient. At drug level, (n=70) of 
the recommendations were observed as dosage changed. 
DRPs totally solved due to recommendations by the clinical 
pharmacist were 69.57% (n=80).
Table 3. Clinical Pharmacist Reccommendations on Drug-Related Problems During Chemotherapy Administration
Domain Recommendations Number of occurrence
(n= )
At patient/carer level
Patient (medication) counselling 50
Patient referred to prescriber 31
Spoken to family member/caregiver 12
At drug level
(Recommendations proposed, approved by prescriber)
Drug changed
(mainly antiemetics, IV fluid) 10
Dosage changed 70
Drug stopped
(mainly antiemetics, IV fluid) 11
Domain Outcome of recommendations Number of occurrence(n= )
Solved Problem totally solved 80
Not solved Problem not solved, lack of cooperation of patient 20
Problem not solved 15
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Generally, there was a significant (p<0.05) increase in 
the occurrence of some ADRs during chemotherapy 
administration as presented in Figures (1 to 4), including 
paleness (P=0.0001), urinary frequency (P=0.003), loss 
of appetite (P=0.0001), nausea (P=0.0001), vomiting 
(P=0.0001), numbness (P=0.0001), ear ringing (P=0.021), 
and fatigue (P=0.0001). After clinical pharmacist 
recommendations and provision of patient education, a 
significant decrease in the occurrence (1st vs. 2nd readings) 
and severity (mild vs. moderate) of adverse drug effects was 
observed as a mild urinary frequency (P=0.0001) and a mild 
vomiting (P=0.0001). Although statistically non-significant, 
there was also a decrease in the occurrence and severity of 
the following adverse drug effects, including mild urine 
burning, mild mouth ulcers, moderate constipation and 
moderate diarrhea.
Figure 1. Adverse Drug Effects During Chemotherapy Administration Regarding Skin
1=the first reading after the 2nd cycle of receiving the chemotherapeutic regimens 
2 =the second reading at the end of the requied chemotherapy protocol schedule
Figure 2. Adverse Drug Effects During Chemotherapy Administration Regarding Urinary System
1=the first reading after the 2nd cycle of receiving the chemotherapeutic regimens 
2 =the second reading at the end of the requied chemotherapy protocol schedule
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Figure 3. Adverse Drug Effects During Chemotherapy Administration Regarding Gastrointestinal System
1=the first reading after the 2nd cycle of receiving the chemotherapeutic regimens 
2 =the second reading at the end of the requied chemotherapy protocol schedule
Figure 4. Adverse Drug Effects During Chemotherapy Administration Regarding Central Nervous System
1=the first reading after the 2nd cycle of receiving the chemotherapeutic regimens 
2 =the second reading at the end of the requied chemotherapy protocol schedule
Discussion
Drug-related problems in cancer chemotherapy are associated 
with severe and undesirable consequences resulting from the 
administration of anticancer agents that are highly toxic and 
most of them have narrow therapeutic index. Furthermore, 
diabetic patients are known to be at risk of drug-related 
problems since those patients commonly receive multiple 
medications due to co-morbid diseases associated with the 
condition (16,17).
As presented in Table (2), a high occurrence of DRPs were 
related to inappropriate IV fluid selection and administration. 
DRPs were also related to to either high or low drug dose. A 
study by Nouran Ameen Hamza et al. supported our findings 
and reported that wrong dose error (n=134), missed dose 
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(n=74), errors in the calculation of the chemotherapy dose 
and protocol breach (n=96) were the most frequent types 
of prescribing errors (18). After the recommendations of 
clinical pharmacist as shown in Table (3), DRPs totally solved 
were 69.57% (n=80). A comparable study showed that 89% of 
clinical pharmacist recommendations were accepted by the 
prescribers (19).
The occurrence of DRPs is of major concern in cancer 
as many studies reported that patients are disposed to 
alter in pharmacokinetic parameters by the disease itself, 
malnutrition, reduced serum-binding proteins levels, 
edema, hepatic and/or renal dysfunction (20). In our study, 
patients were not only supposed to suffer from DRPs due to 
chemotherapy administration, but also they were considered 
as diabetic which is regarded as an additional risk factor 
for the high occurrence of DRPs (17). The occurrence of 
DRPs might also be related either to polypharmacy and/or 
a decrease in cognitive memory function as the majority of 
patients in this study were elders. Many studies showed a 
high occurrence of DRPs, a French study delete this word by 
Slama C. et al. revealed there were more than 300 medication 
errors out of 1262 prescriptions in oncology department 
(21). A study by Chan DCet al. reported a higher percentage 
(35%) of DRPs occurrence in the geriatric population 
(22). Study by Bob W and Ines K. showed that 5.9% of the 
diabetic patients had dosing problems (23). Viktil KK et al. 
found a proportional relationship between the number of 
medications being used and the occurrence of DRPs (24).
The results of our study reflect the important role of clinical 
pharmacist in reducing the occurrence of DRPs. Many 
literatures indicate that pharmacist recommendations is 
important to prevent DRPs and produce improved impact on 
their outcomes (25,26). In our study after clinical pharmacist 
recommendations and provision of patient education, a 
significant decrease in the occurrence and severity were 
observed for urinary frequency, and vomiting. There was 
also a decrease (statistically non-significant) for mild mouth 
ulcers, moderate constipation and moderate diarrhea. As 
the duration of cancer and hence the chemotherapy cycles 
increases, the occurrence of some adverse drug  effects also 
increases (27). The occurrence of ADRs may be related 
to patients’ characteristics such as age, gender (females), 
polypharmacy, and co-morbidities.
Many literatures reported that ADRs occur more commonly 
in the elder females, age-related problems, multiple 
comorbidities, polypharmacy, and previous ADRs (28-30). A 
study by Huan-Keat Chan and Sabrina Ismail assessed the 
most common adverse effects occurred by chemotherapy 
administartion and reported that patients experienced 
(83.3%) nausea, (78.9%) vomiting, (23.3%) loss of appetite 
and (6.7%) peripheral neuropathies (31). The findings of 
a study by Muhammad Shahbaz Aslam showed that after 
chemotherapy administartion, the majority of patients were 
suffering from weakness (95%), fatigue (90%) nausea (77%), 
vomiting (75%) and numbness (49%) (27).
These results support the evidence that a cornerstone of 
a clinical pharmacist in oncology practice is to identify 
ADRs, record their frequencies, report factors that may 
increase their risks, solving and preventing of drug-related 
problems, and provision of information to the medical team 
to prevent future ADRs (32). A study by Huan-Keat Chan 
and Sabrina Ismail reported that majority of patients had 
a desire to receive more information about chemotherapy-
related adverse effects from the clinical pharmacists through 
oral conversation before chemotherapy treatment (27). 
Therefore, effective management of chemotherapy-related 
adverse effects is important to improve quality of life of 
patients, which may eventually influence their willingness to 
complete the treatment (14,33).
Limitations of the study
A main weak of this study was a limited number of the 
participants recruited as they were selected to be diabetic 
patients with new diagnosis of cancer alongside a shortened 
timescale of the study. Further extension of the study duration 
would be required to support more clinical pharmacist 
recommendations even after completion of the required 
chemotherapeutic schedules.
Conclusion
Our study was one of those few that evaluted the role of 
clinical pharmacist in diabetic patients with cancer and 
the results clearly pointed out the vital role of clinical 
pharmacist in reducing and resolving drug-related problems 
of chemotherapy and also revealed that provision of patient 
education offered by the clinical pharmacist is of great 
importance to improve the outcomes of these problems in 
diabetic cancer patients.
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ÖZET
Diyabetli Kanser Hastalarında Kemoterapiyle İlişkili 
Problemler Üzerine Eczacı Önerilerinin Etkisi
Kemoterapi alan kanser hastalarında ilaç kaynaklı problemler, 
normalden daha şiddetli sonuçlar gösterir. Klinik eczacının en 
önemli rollerinden biri ilaç kaynaklı problemlerin belirlenmesi 
ve önlenmesidir. Hasta eğitiminin sağlanması, kemoterapi 
uygulanırken ortaya çıkabilecek ilaç kaynaklı problemlerin 
önlenmesi veya şiddetlerinin azaltılması adına önemli bir 
adımdır. Bu çalışmanın amacı, diyabetli kanser hastalarına 
ait bu problemlerin azaltılması ve çözülmesinde klinik eczacı 
tarafından verilen etkili hasta eğitimi ve yapılan uygun 
önerilerin öneminin anlaşılması ve ilaç kaynaklı problemlerin 
ortaya çıkış sıklığının belirlenmesidir. Çeşitli kanser tiplerine 
ait yeni teşhis konmuş ve kemoterapi alması uygun görülmüş 
olan 50 diyabetli hasta üzerinde prospektif ve tek grup olarak 
yürütülen çalışma, Eylül 2014 ve Nisan 2015 tarihleri arasında 
İstanbul, Türkiye’deki bir eğitim ve araştırma hastanesinde 
gerçekleştirilmiştir. Uygun görülen kemoterapi protokol 
takvimi sırasında, ilaç kaynaklı problemler değerlendirilmiş ve 
kemoterapiye dair eczacı önerileriyle, hastalara uygun eğitim 
verilmiştir. İlaç kaynaklı problemlerin n=65’i uygunsuz IV 
sıvı seçiminden, n=33’ü reçete edilen ilacın dozunun düşük 
olmasından, n=30’u da reçete edilen ilacın dozunun yüksek 
olmasından dolayı ortaya çıkmıştır. Klinik eczacı önerileriyle 
tamamen çözülen ilaç kaynaklı problem yüzdesi %69.57’dir 
(n=80). Solgunluk (p=0,0001), idrar sıklığı (p=0,003), iştahta 
azalma (p=0,0001), bulantı (p=0,0001), kusma (p=0,0001) 
ve uyuşukluk (p=0,0001) belirtilerinde anlamlı bir artış 
görülmüştür. Klinik eczacı önerilerinden ve hasta eğitiminden 
sonra kemoterapiye bağlı yan etkilerden idrar sıklığı (p=0,0001) 
ve kusmanın (p=0,0001) şiddeti ve sıklığında anlamlı azalma 
gözlenmiştir. Bu çalışma, diyabetli kanser hastalarının ilaç 
kaynaklı problemlere ve ilaç yan etkilerine açık olduklarını 
ortaya koymuştur. Klinik eczacının bu tür hastalara anlaşılabilir 
bir eğitim ve bakım sağlaması beklenir. Eczacı önerilerinin 
sonucunda birçok ilaç kaynaklı problemin ve yan etkinin 
önlenmesi ve ortadan kaldırılması sağlanarak hastaların 
kemoterapi kürlerine devam etme isteği artırılabilir.
Anahtar kelimeler: Klinik eczacı önerileri, diabetes mellitus, 
ilaç kaynaklı problemler, ilaç yan etkileri.
Izzettin et al.
Influence of Pharmacist Recommendations for Chemotherapy-Related Problems in Diabetic Cancer PatientsMarmara Pharm J 21/3: 603-611, 2017 611
19. Kuo G, Touchette D, Marinac J. Drug errors and related 
interventions reported by United States clinical pharmacists: 
The American college of clinical pharmacy practice-based 
research network medication error detection, amelioration 
and prevention study. Pharmacother 2013;33: 253-65.
20. Jaehde U, Liekweg A, Simons S, Westfeld M. Minimising 
treatment-associated risks in systemic cancer therapy. Pharm 
World Sci 2008;30:161-8.
21. Slama C, Jerome J, Jacquot C, Bonan B. Prescription errors with 
cytotoxic drugs and the inadequacy of existing classifications. 
Pharm World Sci 2005 ;27:339-43.
22. Chan DC, Chen JH, Kuo HK, We CJ, Lu IS, Chiu LS, Wu 
SC. Drug-related problems (DRPs) identified from geriatric 
medication safety review clinics. Arch Gerontol Geriatr 
2012;54:168-74.
23. Bob W, Ines K. Development of an evidence-based checklist 
for the detection of drug-related problems in type 2 diabetes 
mellitus. Pharm World Sci 2009; 31:580–95.
24. Viktil KK, Blix HS, Moger TA, Reikvam A.Polypharmacy 
as commonly defined is an indicator of limited value in the 
assessment of drug-related problems. Br J Clin Pharmacol 
2007; 63:187-95.
25. Feyer P, Kleeberg UR, Steingräber M, Günther W, Behrens 
M.Frequency of side effects in outpatient cancer care and 
their influence on patient satisfaction—a prospective survey 
using the PASQOC questionnaire. Support Care Cancer 2008; 
16:567–75.
26. Craig P, Dieppe P, Macintyre S, Michie S, Nazareth I, Petticrew 
M; Medical Research Council Guidance. Developing and 
evaluating complex interventions: the new Medical Research 
Council guidance. BMJ 2008;337:a1655.
27. Aslam MS, Naveed S, Ahmed A, Abbas Z, Gull I, Athar MA. 
Side effects of chemotherapy in cancer patients and evaluation 
of patients opinion about starvation based differential 
chemotherapy. J Cancer Ther 2014; 5: 817-22.
28. Atkin PA, Veitch PC, Veitch EM, Ogle SJ. The epidemiology 
of serious adverse drug reactions among the elderly. Drugs 
Aging 1999;14:141-52.
29. Roughead EE, Barratt JD, Gilbert AL. Medication-related 
problems commonly occurring in an Australian community 
setting. Pharmacoepidemiol Drug Saf 2004; 13: 83-7.
30. Steinman MA, Landefeld CS, Rosenthal GE, Berthenthal D, 
Sen S, Kaboli PJ. Polypharmacy and prescribing quality in 
older people. J Am Geriatr Soc 2006;54:1516-23.
31. Chan H-K, Ismail S. Side effects of chemotherapy among 
cancer patients in a Malaysian General Hospital: Experiences, 
perceptions and ınformational needs from clinical 
pharmacists. Asian Pac J Cancer Prev 2014; 15: 5305-9.
32. Baniasadi S, Habibi M, Haghgoo R, Karimi Gamishan M, 
Dabaghzadeh F, Farasatinasab M, Farsaei S, Gharekhani A, 
Kafi H, Karimzadeh I, Kharazmkia A, Najmeddin F, Nikvarz 
N, Oghazian MB, Rezaee H, Sadeghi K, Tafazzoli A, Shahsavari 
N, Fahimi F. Increasing the number of adverse drug reactions 
reporting: the role of clinical pharmacy residents. Iran J Pharm 
Res 2014;13:291-7.
33. Carelle N, Piotto E, Bellanger A, Germanaud J, Thuillier A, 
Khayat D. Changing patient perceptions of the side effects of 
cancer chemotherapy. Cancer 2002;95:155-63.
